Kiniksa Pharmaceuticals International (KNSA) free cash flow

Free cash flow · fiscal 2025
$136.42M

Kiniksa Pharmaceuticals International (KNSA) generated free cash flow of $136.42M in fiscal 2025 (the year ended December 31, 2025). That is 436.8% higher than the $25.41M of fiscal 2024. Figures as of 18 Nov 2026, 12:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$136.42M
Change on fiscal 2024
+436.8%
Highest on record
$136.42Mfiscal 2025
Lowest on record
-$161.57Mfiscal 2019
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kiniksa Pharmaceuticals International free cash flow, in more detail

Across the 9 fiscal years on record (2017–2025), the highest was $136.42M in fiscal 2025 and the lowest -$161.57M in fiscal 2019.

History · 9 fiscal years

Free cash flow by fiscal year

Kiniksa Pharmaceuticals International free cash flow, year by year

Kiniksa Pharmaceuticals International (KNSA) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$136.42M 436.8% up
2024$25.41M 92.9% up
2023$13.17M 131.0% up
2022$5.70M—
2021-$126.71M—
2020-$136.82M—
2019-$161.57M—
2018-$86.30M—
2017-$50.29M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Kiniksa Pharmaceuticals International and comparable companies
CompanyFree cash flowFiscal year
Alkermes ALKS$480.33M2025
PACS Group PACS$155.07M2025
Kiniksa Pharmaceuticals International KNSA$136.42M2025
ImmunityBio IBRX-$309.19M2025
Cytokinetics CYTK-$534.82M2025
ABIVAX ABVX-€161.27M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KNSA

Kiniksa Pharmaceuticals International, figure by figure

Kiniksa Pharmaceuticals International (KNSA) overview: price, valuation and scorecardAll health care companies by market value

Kiniksa Pharmaceuticals International free cash flow: questions and answers

What is Kiniksa Pharmaceuticals International's free cash flow?

Kiniksa Pharmaceuticals International (KNSA) generated free cash flow of $136.42M in fiscal 2025 (the year ended December 31, 2025). That is 436.8% higher than the $25.41M of fiscal 2024.

What are the highest and lowest free cash flow figures on record for Kiniksa Pharmaceuticals International?

Across the 9 fiscal years on record (2017–2025), the highest was $136.42M in fiscal 2025 and the lowest -$161.57M in fiscal 2019.

How is Kiniksa Pharmaceuticals International's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Kiniksa Pharmaceuticals International it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kiniksa Pharmaceuticals International (KNSA) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/KNSA/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.